Trzeciak added: "This new technology is huge, and has the potential to transform the landscape of early detection." He noted that Identafi(TM) 3000 recently received FDA approval.
Oral Cancer Strategy Hinges on Early Detection
Early detection of oral cancer translates into cure rates of greater than 80 percent, which is one reason why the American Cancer Society (ACS) and American Dental Association (ADA) both recommend opportunistic screening for oral cancer.
Yet the National Cancer Institute estimates that only 20 percent of the U.S. population receives an annual oral examination. In fact, the ADA estimates that while 60 percent of the U.S. population visits a dentist every year, fewer than 15 percent of those who regularly visit a dentist report actually having received an oral cancer screening.
Not surprisingly, 40 percent of those diagnosed with oral cancer will die within five years because the majority of those cases will be discovered only as a late-stage malignancy.
Oral cancer is so dangerous because so few patients notice symptoms of the disease in its early stages. It can progress without causing pain or obvious signs. As a result, oral cancer often goes undetected until it has metastasized and spread to another part of the body.
"The bottom line is that we need population-based screening programs to catch the disease as early as possible," Trzeciak said. "It's the only way we're going to beat oral cancer."
About TRIMIRA(TM) LLC
TRIMIRA(TM) LLC is a subsidiary of Remicalm LLC, a privately held medical diagnostic and imaging device company, and is its first subsidiary. Other subsidiaries are working on screening and diagnostic devices for skin, cervical, gastrointestinal, and bladder cancers. Remicalm targets certain f
|SOURCE TRIMIRA(TM) LLC|
Copyright©2009 PR Newswire.
All rights reserved